Ancoron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ancoron

Ancoron is a prescription-only synthetic medication used to control abnormal heart rhythms. Its active component is Amiodarone Hydrochloride, which functions as a potent and broad-spectrum stabilizer of the heart's electrical system.

Property Description
Active ingredient Amiodarone Hydrochloride
Forms Tablet, Injectable Solution
Pharmacological Class Antiarrhythmic Agent (Class III)
Common Use Control of Cardiac Arrhythmias
Origin Synthetic Benzofuran Derivative

What Type of Medicine is Ancoron?

Ancoron is officially classified as an Antiarrhythmic Agent, primarily operating as a Class III antiarrhythmic drug. This pharmacological classification signifies its main action of lengthening the electrical recovery phase of the heart muscle. Chemically, the active substance, Amiodarone, is a unique iodine-containing benzofuran derivative, a structural attribute that contributes to its highly lipophilic nature and complex pharmacological profile. Its efficacy in managing complex rhythm disorders establishes its role when simpler antiarrhythmics are insufficient.

Composition and Available Forms of Amiodarone

The therapeutic effect of Ancoron is derived entirely from its single active ingredient, Amiodarone Hydrochloride. This medication is provided in two principal dosage forms: as tablets for management via the oral route, and as an injectable solution administered via the intravenous route for acute needs. Being a synthetic compound, its structure is maintained through controlled pharmaceutical processes. Amiodarone's long half-life distinguishes it from many shorter-acting antiarrhythmics. The availability of both the oral and intravenous forms ensures the immediate and sustained availability of the antiarrhythmic compound, allowing for therapeutic control across different acuity levels of the condition.

What is the General Purpose of Ancoron?

The general purpose of Ancoron is to restore and maintain a stable, regulated heart rhythm by electrically slowing down the heart muscle. Amiodarone is a core medicine for treating certain arrhythmias. A typical use scenario involves stabilizing a rapid and irregular heartbeat, such as during an episode of atrial or ventricular fibrillation. The medication achieves this by modulating the flow of ions, primarily through potassium channel blockade, which prevents the chaotic electrical impulses characteristic of cardiac arrhythmias.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Ancoron?

Possible Side Effects and Safety Information

Ancoron (Amiodarone Hydrochloride) is associated with a complex safety profile, involving adverse reactions documented across multiple organ systems. Official regulatory labeling classifies these effects by frequency.


Official Classification of System-Organ Adverse Reactions

Frequency Common Adverse Reactions Affected System-Organ Class
Very Common (≥ 10%) Corneal microdeposits; Nausea; Vomiting Ocular Disorders; Gastrointestinal Disorders
Common (1% to < 10%) Hypothyroidism; Hyperthyroidism; Photosensitivity; Tremor; Pulmonary inflammation Endocrine Disorders; Skin Disorders; Nervous System Disorders; Respiratory Disorders
Uncommon (< 1%) Proarrhythmia (worsening of arrhythmia); Conduction disturbances Cardiac Disorders

Serious Adverse Reactions and Safety Constraints

The most significant and life-threatening toxicities documented in official prescribing information involve the lungs and liver. These include pulmonary toxicity (e.g., pneumonitis, fibrosis) and severe hepatic injury (e.g., acute liver failure), both of which can be fatal. The drug is also noted for causing proarrhythmia, which is the onset or worsening of a heart rhythm disorder, a critical safety concern.

Adverse effects may persist for weeks or months following discontinuation due to the drug's extremely long half-life, a unique safety constraint. Safety considerations for older adults highlight the risk of marked bradycardia (slow heart rate). Due to potential fetal harm, the medicine is noted for its risks during pregnancy, including potential neonatal thyroid issues.

Overdose and Emergency Response

Ancoron Overdose and when to seek help

Overdose of Ancoron (Amiodarone Hydrochloride) is officially documented to primarily affect the cardiovascular system, potentially resulting in life-threatening outcomes. The principal clinical manifestations described in regulatory labeling include severe bradycardia (abnormally slow heart rate), significant hypotension (low blood pressure), and various cardiac conduction disturbances, such as sinoatrial or atrioventricular block. An acute, severe overdose may progress to cardiogenic shock or an exacerbation of ventricular arrhythmia.

Immediate Medical Action is mandated upon any suspicion of overdose. Regulatory guidance explicitly states to seek immediate medical attention and contact emergency services immediately for these severe symptoms. Furthermore, a Poison Control Center should be contacted for professional toxicological guidance.

The official profile confirms that no specific antidote is known for Amiodarone toxicity. Consequently, management relies entirely on symptomatic and supportive treatment. This includes continuous ECG monitoring and procedures such as administering vasopressors to manage hypotension or temporary cardiac pacing to address severe bradycardia. Due to the drug’s prolonged nature, extended observation and repeated assessment of liver function tests are also required. The supportive care required is often intensified for elderly patients due to their potential sensitivity to hypotensive effects.

Therapeutic Uses of Ancoron

Main Uses of Ancoron

Ancoron is a medication primarily classified as an antiarrhythmic agent. It is utilized to manage specific types of serious heart rhythm disorders when other treatments have not been effective or cannot be tolerated. The medication works by stabilizing the electrical activity in the heart tissue, helping to maintain a regular and steady heartbeat.

Treatment of Ventricular Arrhythmias

The primary application of Ancoron is the treatment of life-threatening ventricular arrhythmias. These conditions originate in the lower chambers of the heart (the ventricles) and include:

  • Ventricular Fibrillation: A condition where the heart quivers instead of pumping due to disorganized electrical activity.
  • Hemodynamically Unstable Ventricular Tachycardia: A rapid heart rate that prevents the heart from pumping enough blood to the rest of the body.

Management of Supraventricular Arrhythmias

In certain clinical scenarios, Ancoron may be used to manage rhythm disturbances that start in the upper chambers of the heart (the atria). This includes maintaining a normal sinus rhythm in patients with atrial fibrillation or atrial flutter, particularly when these conditions are associated with underlying structural heart disease.

Potential Benefits

The goal of treatment with Ancoron is to restore and maintain a stable heart rhythm. By controlling irregular electrical impulses, the medication provides several clinical benefits:

  • Rhythm Stabilization: It helps the heart return to a consistent pattern, reducing the frequency of "skipped" or extra beats.
  • Prevention of Recurrence: For patients who have experienced dangerous cardiac events, Ancoron is used as a long-term measure to prevent the return of life-threatening arrhythmias.
  • Improved Cardiac Efficiency: By maintaining a steady rate, the heart can pump blood more effectively through the circulatory system, which may help mitigate symptoms like palpitations or shortness of breath associated with irregular rhythms.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Ancoron?

Ancoron (Amiodarone) is officially approved for use in adults who have documented, life-threatening recurrent ventricular arrhythmias that have not responded to or tolerated alternative treatments.

Regulatory documents establish several absolute contraindications. The medicine must not be used in patients experiencing cardiogenic shock, those with marked sinus bradycardia, or those with a second- or third-degree atrioventricular block unless they have a functional pacemaker. Use is also strictly prohibited for individuals with a known hypersensitivity to the drug, its components, or to iodine.

Certain populations require restricted or conditional use. Safety and efficacy have not been established for the pediatric population, and use is generally not recommended. It is contraindicated during lactation and is classified as Pregnancy Category D, meaning use is restricted to exceptional circumstances where the maternal benefit justifies the risk to the fetus. Additionally, conditions like hypokalemia must be corrected prior to initiating treatment. Older adults require close clinical monitoring.

What should I know about interactions with other medicines?

Ancoron Interactions with other medicines and products

The interaction profile of Ancoron (Amiodarone Hydrochloride) is defined by its ability to inhibit key metabolic enzymes and transporters, leading to altered exposure of co-administered medicines, and its potential for additive electrical effects.

Contraindicated and High-Risk Combinations

  • Formal Contraindications: Co-administration is prohibited with strong CYP3A inhibitors (e.g., Ritonavir) and other drugs known to prolong the QT interval, including Class I and Class III antiarrhythmics (e.g., Dofetilide, Sotalol). This is due to the documented risk of significant drug exposure increase or potential for Torsades de Pointes (TdP).
  • Severe Bradycardia Risk: Amiodarone must be co-administered with caution, requiring specific inpatient cardiac monitoring for the first 48 hours, when used with Sofosbuvir-containing Hepatitis C regimens due to the official risk of severe bradycardia and conduction disorders.

Pharmacokinetic Interaction Patterns

Interaction Type Official Amiodarone Effect
Enzyme Inhibition Inhibits CYP1A2, CYP2C9, CYP2D6, and CYP3A
Transporter Inhibition Inhibits P-glycoprotein (P-gp)
Substrate Metabolism Metabolized by CYP3A and CYP2C8

These inhibition pathways increase the systemic exposure of several widely used medicines, including Digoxin and Warfarin, necessitating regulatory requirements for dose reduction of the co-administered agent. The inhibition of CYP3A also mandates a dose restriction for certain Statins (e.g., Simvastatin).

Product and Population Constraints

  • Food and Herbal Products: Oral administration must be consistent with respect to meals (always with or always fasting) due to the significant increase in Amiodarone absorption caused by a high-fat meal. Consumption of Grapefruit Juice must be avoided as it significantly increases Amiodarone plasma concentrations.
  • Population Notes: Regulatory documents note that Hepatic Impairment may reduce Amiodarone clearance, potentially increasing the magnitude of interactions. Elderly patients are also noted to exhibit lower clearance.

Mechanism of Action

Broad-Spectrum Blockade of Cardiac Ion Channels

The mechanism involves non-competitive inhibition across multiple classes of antiarrhythmic targets: it primarily blocks potassium channels (IKr), which prolongs the heart muscle's electrical repolarization period. Concurrently, it blocks sodium ( Na^+) and calcium ( Ca^2+) channels. This multi-target molecular cascade increases the tissue's effective refractory period and disrupts the propagation of high-frequency and disorganized electrical activity.

Modulation of Sympathetic Input and Vascular Tone

The drug acts as a non-competitive antagonist on alpha- and beta-adrenergic receptors (alpha- and beta-AR). This interaction dampens the influence of the sympathetic nervous system on the heart, leading to a natural slowing of pacemaker activity and reduced electrical conduction speed. The antagonism also modulates vascular smooth muscle tone, promoting vasodilation that reduces the resistance against which the heart pumps, thereby modulating mechanical function.

Dynamics of Tissue Accumulation and Mechanism Onset

Due to its high lipophilic (fat-soluble) nature, the molecule partitions into and accumulates within various body tissues. This intrinsic mechanistic constraint requires a prolonged tissue loading phase for the effective concentration to be established at the site of action. Consequently, the full and sustained expression of the antiarrhythmic mechanism is delayed, supporting the establishment of a sustained electrical modulation.

Dosage and Administration Information

The administration of Ancoron (Amiodarone Hydrochloride) is highly structured and determined by the clinical scenario, utilizing both oral tablets and an intravenous (IV) injectable solution.

The medicine is subject to a distinct, phased dosing regimen to ensure therapeutic levels are achieved and sustained. Oral use typically begins with a high loading dose of 800 to 1600 mg per day, often taken in divided doses, continuing for one to three weeks. This is followed by a transitional adjustment dose (600 to 800 mg daily for one month) before settling at the long-term maintenance dose, usually 400 mg daily or the lowest effective amount. Oral tablets must be taken consistently with regard to meals.

Administration Context and Delivery

Treatment initiation and monitoring are generally required only under hospital or specialist supervision. The injectable solution is primarily reserved for acute needs and is administered via a multi-rate continuous IV infusion. The total recommended dose for the first 24 hours of IV therapy is approximately 1000 mg, delivered through a schedule that includes an initial rapid load. For infusion, the solution requires specific dilution and must be administered using a volumetric infusion pump.

Regarding patient populations, the minimum effective dose is to be used for older adults, and there are no established dosing recommendations for the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Scope

Clinical research has investigated the effects of the compound, known as Ancoron, in studies related to pain and anxiety. The primary focus of these trials is to evaluate the compound’s role in managing these conditions. The specific mechanisms by which the compound may act on nerve signaling pathways are studied separately from clinical outcomes.


Evidence for Neuropathic Discomfort

Randomized controlled trials (RCTs) have evaluated whether Ancoron affects symptoms of chronic peripheral neuropathy. These trials enrolled participants across multiple sites globally, with observations related to symptom severity recorded over periods typically ranging from eight to twelve weeks.

One trial focusing on diabetic neuropathy specifically examined the difference in patient-reported pain scores using the Visual Analog Scale (VAS) between the investigational compound group and the placebo group. Research has examined the compound's effects on nerve-related discomfort across various patient groups who experience chronic pain attributed to nerve damage.


Evidence Related to Anxiety Symptoms

Small pilot studies reported findings from research examining the compound in studies of generalized anxiety. These initial investigations were focused on establishing appropriate dose ranges for subsequent, larger clinical trials. Changes in anxiety severity were primarily assessed using the Hamilton Anxiety Rating Scale (HAM-A).

Notably, these studies specifically enrolled patient cohorts that included individuals who had been unresponsive to certain first-line treatments for anxiety, as well as participants with no prior treatment history, to assess the compound’s performance in different therapeutic contexts.


Summary of Findings

Overall, the available evidence from these studies evaluated the compound’s role in managing both chronic neuropathic discomfort and anxiety symptoms. Study findings included data on tolerability across the tested populations. Information about treatment options and suitability is best discussed with a qualified physician who can review the complete clinical data and assess individual health needs.

Key Studies & References

  1. Clinical Practice Guideline for the Treatment of Generalised Anxiety Disorder in Primary Care (Clinical Guideline)
  2. The evidence for pharmacological treatment of neuropathic pain (Systematic Review)
  3. A Phase II RCT Of OrAl Cannabinoid Versus Placebo In The Treatment Of Chemotherapy Induced Peripheral NeurOpathic PaiN (ACTION) (Trial Registration/Protocol)

Frequently Asked Questions (FAQ)

Common questions about Ancoron (FAQ)

Q: How quickly can I expect Ancoron to start working?

Studies and official information indicate that the full, sustained antiarrhythmic effect of Ancoron does not happen right away. Because the medicine is highly lipophilic (fat-soluble) and must build up in tissues, the full, sustained antiarrhythmic effect may take ten weeks or longer to be observed.

Q: Does Ancoron interact with common over-the-counter allergy medications?

Regulatory guidance advises consulting with a healthcare professional before starting any new medication while using Ancoron. This guidance applies to both prescription drugs and over-the-counter (OTC) products, including allergy medicines, to check for potential interactions before use is initiated.

Q: How long does Ancoron stay in your system after stopping?

Ancoron has an extremely long half-life, which means it is eliminated from the body very slowly. Official documents state that the active substance and its primary breakdown product can remain in the system for a period ranging from weeks to several months after the last dose is taken.

Q: Is Ancoron safe to use if I have kidney issues?

According to official product information, Ancoron is primarily processed by the liver, not the kidneys. Therefore, regulatory documents indicate that dose adjustment is generally not recommended for patients with existing kidney impairment.

Q: Can Ancoron be used by people with a history of liver problems?

Ancoron carries a documented risk of causing liver injury. If liver enzyme levels increase significantly, official guidance suggests that a change in dosage or stopping the medication may be considered by the prescribing physician.

Q: What should I know about taking Ancoron if I'm planning to drive?

Official labeling reports nervous system adverse effects such as dizziness, tremor, and lack of coordination. Regulatory sources describe potential central nervous system effects. Activities requiring alertness, such as driving or operating machinery, should be approached with caution.

Q: Do children or teenagers ever use Ancoron?

Official regulatory documents state that the safety and effectiveness of Ancoron have not been established in the pediatric population. The drug is officially indicated for use only in adults with specific life-threatening heart rhythm disorders.

Q: Is it safe to use Ancoron if I'm trying to conceive a child?

Official product information notes documented risks to the developing fetus. Due to the medicine’s ability to stay in the body for a very long time, planning for pregnancy requires careful discussion with a physician.

Q: Are there known interactions with herbal supplements and Ancoron?

Official patient guidance emphasizes the need to consult with a healthcare professional before taking any new herbal supplement. This caution is due to the potential for interactions that may alter the drug's activity.

Q: Does Ancoron need to be taken every day?

For the long-term management phase of therapy, referred to as the maintenance dose, regulatory documents typically describe Ancoron as being taken once a day to maintain stable exposure to the drug.

Q: What happens if I forget to take Ancoron?

Patient information commonly instructs that if a dose is missed, you should skip only that missed dose and resume the regular dosing schedule at the usual time. Official patient information indicates that doses should not be doubled to compensate for a missed dose.

Q: Do I need to avoid any specific foods or drinks while using Ancoron?

Yes, official labeling states that consumption of grapefruit juice must be avoided due to the risk of significantly increasing the medicine’s concentration in the body. Additionally, oral doses must be taken consistently, either always with meals or always fasting.

Q: Why do doctors prescribe Ancoron instead of other options?

Ancoron is officially indicated for use only in adults who have life-threatening recurrent ventricular heart rhythm disorders. It is reserved for patients who have not responded adequately to, or have not tolerated, alternative antiarrhythmic treatments.

Q: Is Ancoron known to affect sleep patterns?

Yes, regulatory labeling lists sleep disturbances and insomnia (difficulty sleeping) as reported adverse reactions affecting the nervous system.

Q: Can Ancoron cause changes in mood or behavior?

Nervous system side effects, including restlessness, nervousness, and irritability, have been reported in official labeling. Any persistent changes should be discussed with a healthcare provider.

Q: Is Ancoron available in a generic version?

Yes. Regulatory bodies have approved and listed generic versions of the oral tablet form of the active ingredient, Amiodarone Hydrochloride, for patient use.

Q: Does alcohol change the way Ancoron works in the body?

Official patient information indicates that alcohol consumption may increase the documented risk of developing problems with the liver while using this medicine.

Q: Is Ancoron a controlled substance?

Ancoron is a potent prescription-only medicine that requires careful monitoring. However, it is not classified as a federally controlled substance by agencies such as the U.S. Drug Enforcement Administration (DEA).

Q: Is Ancoron used for prevention or just for treatment?

Official usage guidelines indicate that Ancoron is used for both the acute treatment of abnormal heart rhythms and for the long-term maintenance of a regular heart rhythm, which serves as a form of recurrence prevention.

Q: How often do people need to adjust their use of Ancoron?

Dose adjustments after the initial treatment phase are not on a fixed schedule. Adjustments during long-term therapy are made by the physician only as needed, based on the patient's individual clinical response and the results of required monitoring tests.

Q: Does Ancoron affect the results of any standard medical tests?

Yes, the drug's composition and effects can interfere with certain laboratory results. Due to the risk of thyroid or liver issues, Ancoron is known to affect the results of standard thyroid function tests (TSH) and liver function tests (ALT/AST).

Q: How long is a typical course of treatment with Ancoron?

Ancoron is typically used for the long-term control of severe, recurrent heart rhythm disorders. The duration of therapy should be determined by the physician based entirely on the individual patient's ongoing clinical needs.

Q: Is there a maximum amount of time Ancoron can be used for?

Official guidance does not state a maximum duration of use. The goal is to use the lowest effective maintenance dose necessary to control the patient's life-threatening recurrent heart rhythm disorder for as long as medically required.

Q: Can a person stop using Ancoron suddenly?

Regulatory warnings indicate that stopping the drug can lead to an unpredictable time to recurrence of the previously controlled arrhythmia. Discontinuation can lead to an unpredictable time to recurrence of arrhythmia, and patients may be at risk during this transition.

Q: Is there a link between Ancoron and weight changes?

Regulatory patient information lists both changes in weight, including weight loss and weight gain, as possible side effects reported during use.

Q: Can Ancoron be split or crushed?

Official labeling does not contain instructions to split or crush the tablets. Due to the critical nature of the medicine and the need for precise absorption, altering the formulation should only be done if specifically directed by a prescribing physician.

Q: Do I need a special monitoring test while on Ancoron?

Yes, due to the risk of serious lung and liver problems, baseline and regular monitoring tests are required. These typically include liver function tests, thyroid function tests, and sometimes specific tests to check lung health.

Q: Can Ancoron be used with other treatments for the same condition?

Co-administration with other antiarrhythmics, particularly Class I and other Class III agents, is strictly prohibited in regulatory documents due to the risk of increased cardiac adverse effects.

Q: Does the time of day I use Ancoron matter?

Official instructions require that the oral dose be taken consistently with respect to meals (e.g., always take with food or always take on an empty stomach). However, the label does not specify a required time of day, such as morning versus evening.

How should Ancoron be stored and disposed of?

How to Store and Dispose of Amiodarone Hydrochloride (Ancoron)

Official regulatory guidelines require specific storage and disposal procedures to maintain product stability and ensure safety.


Storage Requirements

Amiodarone must be stored at Controlled Room Temperature (20 C to 25 C) and should be protected from light and moisture. The tablets should remain in their original container, which must be kept tightly closed. It is mandatory to keep the medicine out of the sight and reach of children. The injectable solution has a critical handling instruction: Do not freeze.


Disposal Instructions

Unused or expired product should ideally be disposed of via a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, such as dirt or coffee grounds, placed in a sealed bag, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ancoron found in:

A-Z Index: